ID: ALA5289682

Max Phase: Preclinical

Molecular Formula: C20H15F4N3O

Molecular Weight: 389.35

Associated Items:

Representations

Canonical SMILES:  O=C1NCCc2c1cnn2-c1cccc(Cc2cc(F)cc(C(F)(F)F)c2)c1

Standard InChI:  InChI=1S/C20H15F4N3O/c21-15-8-13(7-14(10-15)20(22,23)24)6-12-2-1-3-16(9-12)27-18-4-5-25-19(28)17(18)11-26-27/h1-3,7-11H,4-6H2,(H,25,28)

Standard InChI Key:  VUJUPWNIIADCOZ-UHFFFAOYSA-N

Associated Targets(Human)

Probable G-protein coupled receptor 52 435 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 389.35Molecular Weight (Monoisotopic): 389.1151AlogP: 3.91#Rotatable Bonds: 3
Polar Surface Area: 46.92Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.02CX Basic pKa: 0.51CX LogP: 3.98CX LogD: 3.98
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.69Np Likeness Score: -1.27

References

1. Poulter S, Austin N, Armstrong R, Barnes M, Bucknell SJ, Higueruelo A, Banerjee J, Mead A, Mould R, MacSweeney C, O'Brien MA, Stott LA, Watson SP..  (2023)  The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders.,  14  (4): [PMID:37077397] [10.1021/acsmedchemlett.3c00052]

Source